Biogen

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,500

Employees7,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,500

Employees7,500

BIIB Key Statistics

Market cap

32.21B

Market cap32.21B

Price-Earnings ratio

38.28

Price-Earnings ratio38.28

Dividend yield

—

Dividend yield—

Average volume

778.03K

Average volume778.03K

High today

$218.29

High today$218.29

Low today

$214.89

Low today$214.89

Open price

$216.41

Open price$216.41

Volume

145.72K

Volume145.72K

52 Week high

$225.80

52 Week high$225.80

52 Week low

$135.39

52 Week low$135.39

Stock Snapshot

The current Biogen(BIIB) stock price is $217.98, with a market capitalization of 32.21B. The stock trades at a price-to-earnings (P/E) ratio of 38.28.

During the trading session on 2026-09-16, Biogen(BIIB) shares reached a daily high of $218.29 and a low of $214.89. At a current price of $217.98, the stock is +1.4% higher than the low and still -0.1% under the high.

Trading volume for Biogen(BIIB) stock has reached 145.72K, versus its average volume of 778.03K.

The stock's 52-week range extends from a low of $135.39 to a high of $225.80.

BIIB News

Barchart 6h

Is Biogen Stock Outperforming the S&P 500? - Barchart.com

...

TipRanks 7h

Eisai, Biogen announce Leqembi Pen has been approved in Japan

Eisai (ESAIY) and Biogen (BIIB) announced that Leqembi Pen, the subcutaneous formulation of the anti-amyloid beta protofibril antibody Leqembi has been approved...

Simply Wall St 15h

Biogen Wins China Approval For At Home Weekly Alzheimer’s Treatment

Biogen (NasdaqGS:BIIB) and Eisai received China NMPA approval for a self-administered subcutaneous LEQEMBI formulation for early Alzheimer's disease. The new L...

Analyst ratings

67%

of 36 ratings

Buy

66.7%

Hold

30.6%

Sell

2.8%

More BIIB News

Nasdaq 4d

Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology

Biogen (NASDAQ:BIIB) executives said the company is focused on diversifying beyond its historical neurology concentration, advancing a broader late-stage pipeli...

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.